8 February 2021
S4 CAPITAL PLC
("S4 Capital" or the "Company")
Notification of transactions by Persons Closely Associated ("PCA") of Persons Discharging Managerial Responsibility ("PDMRs")
The Company was notified on 5 February 2021 that Lawshare Nominees Limited, the nominee of a self-invested pension plan which is a PCA of Peter Miles Young, a non-executive director, had acquired 20,000 ordinary shares of 0.25p each in the capital of the Company.
Following the above acquisition, the PCA holds 50,000 ordinary shares in the capital of the Company.
The Notification of Dealing Form for Peter Miles Young as a PDMR can be found below. This notification is made in accordance with the Market Abuse Regulation.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated
|
|||||||
|
a) |
Name
|
Lawshare Nominees Limited |
||||||
|
2 |
Reason for the notification
|
|||||||
|
a) |
Position/status
|
PCA of Peter Miles Young |
||||||
|
b) |
Initial notification/ Amendment
|
Initial |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
|
a) |
Name
|
S4 Capital plc |
||||||
|
b) |
LEI
|
21380068SP9V65KPQN68 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 25 pence each
GB00BFZZM640 |
||||||
|
b) |
Nature of the transaction
|
Share acquisition
|
||||||
|
c) |
Price(s) and volume(s)
|
|
||||||
|
d) |
Aggregated information
- Aggregated volume
- Price
|
|
||||||
|
e) |
Date of the transaction
|
2 February 2021 |
||||||
|
f) |
Place of the transaction
|
XLON
|
||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
